Picard Medical Q3 revenue up 35% to $1.19M; IPO nets $15.5M in September

Picard Medical, Inc.

Revenue $1.19M (+35% YoY); gross loss narrowed 81% to $0.13M; operating loss $3.36M vs $3.77M.
Net loss $22.7M includes $12.4M non-cash derivative revaluation charge upon IPO debt conversion.
IPO completed Sept 2: $19.5M gross proceeds ($15.5M net); retired convertible debt.
Appointed independent directors Sam Van and George Ye; patent granted for next-gen Emperor artificial heart.
Year-to-date revenue $3.93M (+11%); operating loss $10.3M; EPS ($0.96) vs ($1.79) prior.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.